Dr. Jinsong Liu is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center since 2009. He received his medical degree from Shanghai Medical University 1983 and completed his Ph.D. from Case Western Reserve University in 1991, and post-doctoral training at the University of Michigan in 1993, pathology residency and surgical pathology fellowship training at New York University in 1999. Dr. Liu is an internationally recognized for his expertise in diagnostic pathology and research achievements in ovarian cancer. Dr. Liu has co-authored 213 original publications and has been an editorial member of several reputable journals.
Clinical Medicine, Clinical Teaching, Family Medicine
Shimon Slavin, MD, Professor of Medicine, pioneered the use of personalized anti-cancer immunotherapy mediated by donor lymphocytes and innovative methods for stem cell transplantation for cure of malignant and life-threatening non-malignant disorders, including treatment of autoimmune diseases and induction of transplantation tolerance to bone marrow and organ allografts. More recently, Slavin pioneered the use of multi-potent mesenchymal stromal cells for multi-system regenerative medicine. Slavin authors 4 books, >660 scientific publications and serves on many editorial boards and many national and international advisory boards. Slavin received many international awards in recognition of his contributions for treatment of cancer and non-malignant disorders.
Suparno Chakrabarti is the Head of the Dept for Blood and Marrow Transplantation and Hematology at Dharamshila Narayana Hospital and Research Centre, and Cellular Therapy & Immunology at Manashi Chakrabarti Foundation, India. He initiated the first Haploidentical BMT program in India and along with Dr. Sarita Jaiswal and has developed this as a sustained alternate donor program with over 125 Haploidentical transplants in the past 8 years. They have innovated newer methods of carrying out haploidentical BMT in patients with advanced leukemia as well as aplastic anemia with excellent results. His key area of research is Transplant immunology in relation to Haploidentical BMT. Dr. Chakrabarti trained in Internal Medicine at PGIMER, Chandigarh in India. Subsequently, he spent 13 years in the UK, initially as a research fellow and subsequently as a consultant in the field of BMT. During this period, he played a substantial role in developing Campath-1H based T cell depletion and reduced-intensity conditioning. The bulk of his research also focused on post-transplant virus infections and immune reconstitution. Dr. Chakrabarti received FRCPATH based on his published work. He has over 100 publications to his credit. He also runs a charitable organization for children with blood diseases. Key areas of Research: Haploidentical HCT; NK cell Biology; Post-transplantation Immune reconstitution; Transplantation tolerance.
Haploidentical HCT; NK cell Biology; Post-transplantation Immune reconstitution; Transplantation tolerance.
P K Sasidharan is the former Professor and Head, Department of Medicine and Haematology, Government Medical College Kozhikode, Kerala, India. Dr. Sasidharan completed his MBBS from Calicut University, securing gold medal for highest marks in Medicine, and had MD from PGIMER Chandigarh. His career spanning over more than three decades has been recognized with several awards. These include, Calicut Medical College Alumni Oration, G. K. Warrier Memorial Oration, National Hypertension Oration, 'Netaji Oration', Lifetime achievement award, Fellowships of Indian College of Physicians, Fellowship of the Royal College of Physicians (Glasgow) and of International Medical Science Academy. He has to his credit 92 publications in journals, including the landmark studies on Vitamin D deficiency and on SLE. He has contributed chapters in text books of Medicine and Haematology and is the principal author of a popular textbook Doctors’ Pocket Companion and had published a book on social aspects of health, HEAL-THY INDIA
Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division & De la Parra Mobile Solutions, while also being the President of PetroM Renewable, VP of Operations & Strategy at PetroM Logistics, both divisions of PetroM Corp. Former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty & a member of the Board of Advisors. Former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also served as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and former Digital Media Director at Bioquark, Inc. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.
Neuroscience, Regenerative Medicine, Continued Medical Education, Information & Communications Technology, Biotechnology, Social Development
Vitaly Ovchinnikov has completed his PhD at the age of 26 years from University of Kazan (Russia). He is professor at Kazan national research technical university (KNITU-KAI). He has published more than 100 papers in reputed journals.
Dr Myles Suehiro completed his graduation from University of Colorado Boulder in 1965. He is a recipient of several fellowships and certification in Internal medicine including Fellowship in Anti-Aging Regenerative and Functional Medicine. He worked as an Assistant Professor at Charles R. Drew Postgraduate Medical School till 1986, after which he was appointed as the Director of I.C.U. at City View Hospital, Los Angeles and Medical Director at Cardio-Pulmonary Lab in 1990. He holds immensely vast experience in the field of medicine (more than 45 years) and is interested in the potential of treating rare disorders with the help of regenerative and functional medicine. At present he works as the Director of the Hawaii Institute for Health and Healing, LLC.
Systems approach in Regenerative and Functional Medicine
Dr. Yunyuan Li has completed his Ph.D. in 2005 from the University of Alberta, Canada. He is a currently a senior researcher at Burn and Wound Healing Research Laboratory at the University of British Columbia, Canada. His research interests were focused on the roles of hematopoietic cell-derived multi-potent stem cells in skin wound healing, hair follicle regeneration, and inflammation. Till now, Dr. Li has published over 40 articles in peer-reviewed journals.
Hematopoietic cell-derived multi-potent stem cells in skin wound healing
Dr. Wa Xian received her Bachelor’s degree in Biochemistry from Nankai University in China and Ph.D. degree in Molecular Genetics at the University of Texas Graduate School of Biomedical Sciences in Houston, focusing on master regulator genes of cell proliferation and lineage specification during early neural development. The support of a DOD breast cancer fellowship enabled Dr. Xian’s postdoctoral studies with Prof. Jeffrey Rosen at the Baylor College of Medicine. There she used a combination of ligand-induced dimerization strategies and a mammary epithelial 3D culture system to address the role of fibroblast receptor tyrosine kinase signaling in the evolution of breast cancer. In 2008, Dr. Xian moved to Harvard Medical School under the direction of Prof. Christopher Crum, Director of Women’s and Perinatal Pathology at the Brigham and Women’s Hospital to study the origin and evolution of ovarian cancer. Dr. Xian continues to work very closely with Prof. Crum on the origins and chemotherapy resistance problem in high-grade ovarian cancer. In 2009, Dr. Xian was appointed Principal Investigator at the Institute of Medical Biology of the Agency for Science, Technology, and Research in Singapore, where she jointly oversaw a highly interactive group of postdoctoral fellows, graduate students, and research assistants with Prof Frank McKeon of the Genome Institute of Singapore devoted to the cloning of stem cells of regenerative tissues and using advanced technologies to understand the genetics of their self-renewal, commitment, and differentiation. In 2013, Dr. Xian returned to the US and initiated multiple projects related to inflammatory diseases and cancer with colleagues at the University of Connecticut Health Center. In 2015, Dr. Xian received the Rising Stars Award from the Cancer Prevention & Research Institute of Texas (CPRIT) and was recruited to the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.
Biomarkers and molecular imaging in gastrointestinal cancers.
Professor Ahmed Hashash has completed his PhD from Manchester University, UK. He is a fellow of the California Institute of Regenerative Medicine (CIRM) and New York University Medical School (MSSM), USA. Prof. Ahmed Hashash worked as a senior biomedical research scientist at Mount Sinai School of Medicine of New York University and Children’s Hospital Los Angeles. He was Assistant Professor and Principal Investigator of Stem Cell & Regenerative Medicine at Keck School of Medicine and Ostrow School of Dentistry of The University of Southern California, USA. In 2016, Prof. Hashash has joined The University of Edinburgh, Edinburgh Medical School-Zhejiang International Campus, (ZJU) as Tenure-Track Associate Professor and Senior Principal Investigator of Biomedicine, Stem Cell & Regenerative Medicine. He is also adjunct Professor at the School of Basic Medical Science and School of Medicine, Zhejiang University. Prof. Hashash has several breakthrough discoveries in genes/enzymes that control stem cell behavior and regenerative medicine. He has published more than 25 papers in reputed international journals and serving as an editorial board member of repute. Prof. El-Hashash acts as a discussion leader at the prestigious Gordon Research Seminar/Conference in USA, and a Peer Reviewer/ International Extramural Review for The Medical Research Council (MRC) grant applications, London, UK. He is invited to speak at several international conferences in USA, Spain, Greece, Egypt and China. He is the editor or author of several books on stem cell and regenerative medicine.
Stem Cell Therapy of Diseases & Cell and Developmental Biology
Bekir Cinar completed his Postdoctoral Fellowship, Boston Children’s Hospital, Harvard Medical School (HMS), Boston, MA (2002-2006) and Ph.D. from Department of Biochemistry and Molecular Genetics, School of Medicine University of Virginia, Charlottesville, VA (1995-2002), D.V.M., Veterinary Medical School, Ankara University, Ankara, Turkey (1987-1992). Currently he is working as Associate Professor, Department of Biological Sciences, Clark Atlanta University (CAU), Atlanta, GA 2015 to present. Presently, He is also member of the Center for Cancer Research and Therapeutic Development at CAU and a member of the NCI-designated Winship Comprehensive Cancer Center at Emory University. Prior to joining CAU, Dr. Cinar was Assistant Professor of Medicine-Hematology/Oncology and Biomedical Sciences at Cedars-Sinai Medical Center, where he was a member of Samuel Oschin Comprehensive Cancer Institute.
His research focus is on Signal Transduction, gene Expression, genomics, Proteomics, Bioinformatics, 3DCell Cultures
A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.
Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.
Ming Pei completed his PhD from Beijing University, China and Postdoc training from Harvard-MIT Division of Health Sciences and Technology, USA. Currently he is a tenured Professor and Director of Stem Cell and Tissue Engineering Laboratory in the Department of Orthopaedics, West Virginia University, USA. He has over 100 publications that have been cited over 3100 times, and his publication H-index is 32 and has been serving as an editorial board member of reputed Journals.
Stem cells, Tissue engineering, Biomaterials
Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild-StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell Based Therapy which he believes is the solution to address the limitations of conventional therapeutic modalities. To this effect, he underwent and continues to undergo intensive training in the United States. He has devised personalized treatment protocols in cell-based therapy for more than 75 health conditions. Dr. Mahajan is a Life member and Joint Secretary of The Stem Cell Society of India as well as Vice President of Anti-Aging Foundation, Delhi and Scientific National Advisor, Indian Stem Cell Study Group. He has been appointed as Hon. Associate Professor of Regenerative Medicine and Cell Based Therapy at Dr. R N Cooper Hospital, Mumbai and Faculty for MD Transfusion Medicine at KEM Hospital, Mumbai. Examiner for various fellowship courses with D.Y. Patil Institute, Kolhapur. Dr. Mahajan’s academic collaborations include being a Member of board of studies in ITM University, Raipur / MUHS, for PhD courses, M.Sc. and Fellowship Programs in stem cells and regenerative medicine. Among his international associations, a clinical trial in collaboration with the Ohio State University, USA on Cell Based Therapy for Avascular Necrosis is noteworthy, wherein Dr. Mahajan is a Principal Investigator. He is also a principal investigator in collaboration with Indiana University, Indianapolis under the guidance of Dr Chandan Sen to conduct the first human clinical trials using TNT technology in India. His recent international ventures include extension of StemRx facilities in Africa and collaboration with an organization in Japan to launch NK cell (cancer immunotherapy) technology for solid tumours in India. His company StemRx is also working on CAR-T cells technology in India. He has published an international patent for treatment of Avascular Necrosis using Regenerative Medicine approach and Indian patents for Avascular Necrosis, Ankylosing Spondylitis, Ischemic-tolerance Mesenchymal Stem Cell treatment/technology and isolation of dental pulp stem cells. He has 13 paper publications to his credit. Dr Mahajan has also been appointed by Government of India and Government of Maharashtra as consultant and panel doctor with the director general of shipping and labour department. Dr Mahajan is also associated with scholarly Journals for reviewing articles / research publication. Some of these are • Member, Editorial Board – ASMI • Member Editorial Board for reviewing scholarly articles, Gavin Publishers • Member Health Council – Head Hunt • Expert Reviewer – Journal of Scientific Research & Report • Expert Reviewer – British Journal of Medicine & Medical Research His drive to achieve tangible outcomes in research and therapy has earned him recognition and several awards in the field of healthcare—Paris Appreciation Award and National Awards for Excellence in Healthcare (Clinical Research category) for 2 consecutive years (2016 & 2017) to name a few. Recently he has also been featured in the Forbes Healthcare magazine for his pioneering work in the field of stem cell
Regenerative Medicine and Stem Cell
Dr. Carolle-Laure KPOUMIE has worked as pediatric assistant physician in pediatric’s department of faculty of medicine in Cameroon, as clinical researcher methodology, scientific writing, public health, oncology, internal medicine and continued her career in pharmaceutical industries in France. She participates in many congress with studies made in hospitals on relevant cases in the framework Studies and clinical research. She became head of department, director, head of district where she continued her research, writing of treatment protocols in different departments for common pathologies encountered in her context, managing Epidemic crisis such as cholera, meningitis, avian influenza, yellow fever and organizes campaigns on infectious diseases ,HIV, cardiovascular diseases, family planning, research on severe malaria, malnutrition in Children and participates in studies on neonatal mortality in underdeveloped countries. She work on ADR in hospital following drug administration, pharmacovigilance, vaccinovigilance, biovigilance, materiovigilance, pharmacovigilance in underdeveloped countries, articles, medical information and therapeutic safety, clinical trials, Post-marketing, and other’s studies.
Dr. Osorio is a innovative businessman with an distinct entrepreneurial mindset concentrated in adding value on the areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the CEO of RegenerAge Clinic and RegenerAge Beauty. VP and Clinical Developer for Bioquark, Inc., CCO at Reanima Advance Biosciences Project. President at Dr. Jois an anti-aging, beauty, and cosmetic products endorsement company. VP and Chairman of the WAMS Americas Division. Earned MD degree at Westhill University. Diplomate in aesthetic medicine (UAG), Advance Fellow by the ABAARM, visiting scholar at UNC at Chapel Hill in Dermatology. Fellow in Stem Cell Medicine by the A4M and USF, Business Diplomate at ECA, enrolled Master on Health Sciences at Victoria University. Has appeared on several occasions on International media, some of his latest broadcast appearances are CNN español, TV Azteca, Excelsior Newspaper, Medicable, PharmaBoard Room, and Podcasts among others. His public appearances as a speaker at the 2018 RAADfest (San Diego), 3rd International Conference on Molecular Medicine and Diagnostics (Dubai), Global Academic Business Forum on Tissue Engineering and Regenerative Medicine (Baltimore), Second International Congress on mHealth (Shiraz), 6th International Conference on Tissue Engineering and Regenerative Medicine (S.F), 11th World Congress on Cell & Tissue Science (Tokyo), 17th International Conference on Neurology and Neuroscience (Toronto), 9th International Conference & Exhibition on Tissue Science and Regenerative Medicine (Las Vegas) among others, makes him a pioneer on the Regenerative+Reprogramming Medicine Field. His passion for football, brought as a result the Dr.Jois Foundation A.C aimed at helping those American football athletes who have sustained injury get another chance through the Regenerative & Reprogramming Medicine.
Regenerative Medicine, Anti-Aging Medicine.
DR. ALAIN L. FYMAT, PhD, PhD is a medical-physical scientist and an educator. He is the current President/CEO and Professor at the International Institute of Medicine & Science with a previous appointment as EVP/COO and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He is also Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and International Organizing Committee member at several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has published ~ 425 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of 54 scientific Journals. Dr. Fymat is a Board member of several institutions, a member of the New York Academy of Sciences and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO.
Dr. Fymat’s current research interests lie at the interface between science and medicine, particularly molecular/personal/precision medicine, nanomedicine, human genetics/epigenetics/ecogenetics, and pharmacogenomics. His most recent publications deal with magnetic resonance Imaging with nanocontrasting materials, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery including across the brain protective barriers, and drug manufacturing in Africa.
Dr. Murugan Ramalingam is Professor at the Centre for Biomaterials, Cellular & Molecular Theranostics, VIT University, India. He hss also Adjunct Professor at the Tohoku University, Japan and Professeur des Universite at the Faculté de Chirurgie Dentaire, Université de Strasbourg, France. He has worked at the WPI Advanced Institute for Materials Research, Japan, as an Assistant Professor. He has also worked at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH), under the U.S. National Academies Associateship program. He received his Ph.D. in Biomaterials from the CSIR-Central Leather Research Institute, University of Madras. He has also undergone training in Ethical and Policy issues on Stem Cells from Harvard University, USA, and in Operations Management from the University of Illinois-Chicago. His current research interests are focused on the development of multiphase biomedical materials, through conventional to nanotechnology to biomimetic approaches, microfabrication and bioprinting, cell patterning, stem cell differentiation, tissue engineering and drug delivery. He is the author of ~300 publications, including 20 textbooks relevant to nanotechnology, biomaterials, stem cells, tissue engineering and regenerative medicine. His current h-index is 40 with ~9400 citations. He has delivered several keynote/invited talks and has chaired/organized several international conferences related to Biomaterials, Bioprinting, Nanobiotechnology, Stem Cells and Tissue Engineering. He also serves as a board member of several international scientific and research committees in various public and private bodies and grant reviewer of various international funding agencies. He serves on the editorial boards of multiple biomaterials and tissue engineering-related journals, including the Editor-in-Chief of the Journal of Biomaterials and Tissue Engineering and the Journal of Bionanoscience. He is a recipient of several prestigious fellowships and awards, including CSIR Fellowship (India), Singapore Millennium Fellowship (SMF) (Singapore), NRC National Academies Fellowship (USA), Nationale Professeur des Universités (France), Fellow of Royal Society of Biology (UK), Fellow of Institute of Nanotechnology (UK) and Fellow of Royal Society of Chemistry (UK).
Stem Cell Research,Tissue Engineering
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.
Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.
Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
Dr. Yusuke Yamamoto completed his Ph.D. in Molecular Physiology from Waseda University, Japan in 2008. He further pursued his postdoctoral studies under the supervision of Prof. Frank McKeon and A/Prof. Wa Xian at Genome Institute of Singapore. Presently, he is working as a Senior Staff Scientist at National Cancer Center Research Institute, Japan. He has been interested in how adult stem cells maintain their stemness throughout the lifespan as well as identifying cell-of-origin in esophageal adenocarcinomas and high grade serous ovarian carcinoma, which are the most aggressive type of cancers with poor prognosis. With his outstanding research work, he has published more than 40 papers in peer-reviewed journals, including Nature and Cell and holds one US patent on ‘Nanobio device of imitative anatomy structure’ in 2010 while another one, ‘Novel Diagnosis and Therapeutic Targets for Cervical Cancer’ is in the pipeline. He has presented his various research work in 15 national and international conferences and is a member of The Molecular Biology Society of Japan, Japanese Cancer Association and The Japanese Biochemical Society.
Takashiro AKITSU, Ph.D. is a full Professor for the Department of Chemistry, Faculty of Science Division II at Tokyo University of Science. He completed his undergraduate school training (chemistry) from Osaka University, Japan and his graduate school training (physical & inorganic chemistry, especially coordination, crystal, and bioinorganic chemistry) from Osaka University (Ph.D. 2000). After Keio University and Stanford University, He moved to the current affiliation since 2008. Dr. Akitsu has published up to about 180 articles in peer-reviewed journals and has had posters presented at international level. He has been a peer reviewer of many journals and acted as an organizing committee of several international conferences.
Short Biography Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals/other international journals. He is Advisory Board Member for Photon Journal. He is a Fellow of the International Agency for Standards and Ratings (IASR). He conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. He is Chief Editor for International Journal of Diabetes Research (2014-2019), Research and Reviews: Neuroscience (2016-2019) and Journal of Diabetes and Clinical Studies (2017-2019). He is BIT Member (BIT Congress. Inc) with an H-index of 65 and Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu with citations >4800. Researchgate Analysis: RG score (>96%) of international Scientists. He acquired 71 International Certificates. He is a reviewer for approx. 47 journals over the past five years. Now he is in the 98th percentile as assessed for Publons users by merit. He is Advisory Committee and Organizing Board Member for various international conferences (2018-2019).
Haploidentical HCT; NK cell Biology; Post-transplantation Immune reconstitution; Transplantation tolerance.